Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$36.02M$36.02M+13.4% vs Q2 2023 Net Income-$9.24M-$9.24MN/M vs Q2 2023 EPS Diluted-$0.06-$0.06N/M vs Q2 2023 Gross Profit$25,506,000+119.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,604,000N/M Margins · derivedGross margin70.8%+34.3 pt vs Q2 2023
Operating margin-17.9%+115.6 pt vs Q2 2023
Net margin-25.6%+106.8 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 6, 2024 · 37 d after period end